NCT06812832 Simethicone as Part of ERAS in Bariatric Surgery Patients
| NCT ID | NCT06812832 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Madigan Army Medical Center |
| Condition | Simethicone |
| Study Type | INTERVENTIONAL |
| Enrollment | 260 participants |
| Start Date | 2025-04-08 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 260 participants in total. It began in 2025-04-08 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
By conducting this study, we hope to assess if simethicone (also known as Gas Relief or GasX) has an effect on improving gas pain and bloating specifically in patients undergoing foregut procedures to include bariatric procedures (sleeve gastrectomy, Roux-en-Y gastric bypass), hiatal hernia, and gastric surgery. The purpose of this research is to gather information on the safety and effectiveness of simethicone. Simethicone (more commonly known as Gas Relief or Gas-X) relieves pressure, bloating, and fullness commonly referred to as gas. It is FDA approved. The use of this medication in this research study is consistent with labeling indications.
Eligibility Criteria
Inclusion Criteria: * Foregut procedures Exclusion Criteria: * Non-foregut procedures * Allergy to simethicone * Pregnancy or breastfeeding * Minors under 18 years of age
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06812832 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Simethicone. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06812832 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06812832 currently recruiting?
Yes, NCT06812832 is actively recruiting participants. Contact the research team at brooklyn.c.williams3.mil@health.mil for enrollment information.
Where is the NCT06812832 trial being conducted?
This trial is being conducted at Tacoma, United States.
Who is sponsoring the NCT06812832 clinical trial?
NCT06812832 is sponsored by Madigan Army Medical Center. The trial plans to enroll 260 participants.